EYEN Key Statistics, Chart & Performance
The current stock price of EYEN is 15.82 USD. In the past month the price increased by 649.76%. In the past year, price decreased by -77.32%.
EYEN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EYEN. When comparing the yearly performance of all stocks, EYEN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
EYEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EYEN. EYEN has a bad profitability rating. Also its financial health evaluation is rather negative.
EYEN Financial Highlights
Over the last trailing twelve months EYEN reported a non-GAAP Earnings per Share(EPS) of -34.16. The EPS increased by 43.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -708.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EYEN Forecast & Estimates
8 analysts have analysed EYEN and the average price target is 163.2 USD. This implies a price increase of 931.61% is expected in the next year compared to the current price of 15.82.
For the next year, analysts expect an EPS growth of 33.51% and a revenue growth 400.98% for EYEN
EYEN Ownership
EYEN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 1T | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 578.208B | ||
| MRK | MERCK & CO. INC. | 22.54 | 302.633B | ||
| PFE | PFIZER INC | 9.06 | 154.765B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 126.196B | ||
| ZTS | ZOETIS INC | 18.55 | 56.153B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.774B | ||
| VTRS | VIATRIS INC | 5.76 | 16.793B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 222.91 | 9.202B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EYEN
Company Profile
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Company Info
EYENOVIA INC
295 Madison Ave Ste 2400
New York City NEW YORK 10017 US
CEO: Tsontcho Ianchulev
Employees: 14
Phone: 18137669539
EYENOVIA INC / EYEN FAQ
Can you describe the business of EYENOVIA INC?
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Can you provide the latest stock price for EYENOVIA INC?
The current stock price of EYEN is 15.82 USD. The price increased by 49.81% in the last trading session.
Does EYEN stock pay dividends?
EYEN does not pay a dividend.
How is the ChartMill rating for EYENOVIA INC?
EYEN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does EYENOVIA INC have?
EYENOVIA INC (EYEN) currently has 14 employees.
Can you provide the market cap for EYENOVIA INC?
EYENOVIA INC (EYEN) has a market capitalization of 80.68M USD. This makes EYEN a Micro Cap stock.